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Abstract
Background: Patients with multiple myeloma are generally immune-compromised either due to pronounced
depression in primary antibody responses or because of anti-myeloma therapy. Infection is a major risk factor for
early deaths among these patients. The impact of blood stream infections (BSI) on newly diagnosed myeloma
patients has been less studied. We aimed to study the incidence and risk factors of BSI within 3 months after
diagnosis of multiple myeloma in a tertiary referral center.
Methods: Between November 2002 and December 2008, consecutive patients with multiple myeloma in Taipei
Veterans General Hospital were retrospectively enrolled. Characteristics of patients with or without BSI were collected.
Possible factors associated with development of BSI were analyzed by Cox regression.
Results: There were a total of 222 patients. The incidence of BSI within 3 months after diagnosis is 11.7%. The patients
with BSI had poorer survival outcomes than those without (mortality rate: 50% vs. 20.9%, p < 0.001). Moreover, advanced
International Staging System stage (stage III vs. I/II: odds ratio [OR] 2.69, p = 0.049) and poor Eastern Cooperative Oncology
Group (ECOG) performance status (ECOG > 2 vs. ≤ 2: OR 3.58, p = 0.005) were the independent risk factors of BSI, whereas
immunoglobulin deficiency and low absolute lymphocyte count were not associated with risk of BSI development.
Conclusions: Our study highlights the characteristic of myeloma patients with BSI and the importance of disease and
host factors on risk of BSI. Myeloma patients with risks of BSI should be properly managed to reduce early mortality.
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Background
Early death in multiple myeloma (MM) is usually attrib-
uted to combined effects such as old age, active disease,
comorbidities, and anti-myeloma therapy. Earlier series
had showed 10 to 25% of patients dying within 6 months
of diagnosis [1–3]. Auguston et al. reported a incidence
of 10% (299/3107) patients die within 60 days of diagno-
sis of MM, and the major cause of death are infection
and renal failure [4].
The increased susceptibility to bacterial infection in
MM patients is complicated and multifactorial. Though
impaired antibody production is very likely to be the
main cause of infection at disease onset [5], other factors
such as poor response following immunization, renal
function impairment, defective opsonization, decreased
granulocyte adhesiveness, impaired leukocyte migration,
chemotherapy associated granulocytopenia, and high-
dose dexamethasone all play their roles [6]. Infection is
common in patients with newly diagnosed multiple
myeloma and can be the initial presentation and the
leading cause of death. In an earlier study, pulmonary
and urinary tract infection occur more frequently [7],
and infection not only occurs as the presenting feature
in about 15% of patients with MM, but also is the
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leading cause of mortality. In another recent study,
among the multiple myeloma patients with bacterial
infection as the initial presentation, musculoskeletal infec-
tions and pneumonia are the leading cause of infection [8].
With the progress of anti-myeloma therapy and best
supportive care, major changes have occurred in the
spectrum of causative organisms. The relationship be-
tween bloodstream infection (BSI) with associated
pathogen and early mortality in newly diagnosed MM,
however, is too few to be mentioned in literature. The
main aim of this study is to determine the impact of BSI
on the outcome of newly diagnosed MM patients and
the risk factors of BSI. We believe that the knowledge of
this analysis will raise awareness of early mortality seen
in myeloma and may help with developing strategies for
its prevention and treatment.
Methods
Data collection
This study was approved by the Institutional Review
Board of Taipei Veterans General Hospital. Between
November 2002 and December 2008, consecutive
patients diagnosed with multiple myeloma in Taipei
Veterans General Hospital were eligible for retrospective
screening. A total of 252 patients were enrolled. There
were 30 patients that were excluded due to being previ-
ously treated at other hospitals or for not being consist-
ent with the criteria for symptomatic myeloma as
defined and published by the International Myeloma
Working Group [9]. Patients aged < 65 years old, or can-
didates for autologous stem cell transplantation (ASCT),
received either vincristine/doxorubicin/dexamethasone
(VAD) based regimen, thalidomide based regimens, or
bortezomib based regimen as induction chemotherapy.
In contrast, patients aged ≧ 65 years old, or not a candi-
date for ASCT received either melphalan/prednisolone
(MP), thalidomide based regimens or bortezomib based
regimen as palliative chemotherapy. Patients’ demo-
graphic data and clinical characteristics were obtained
from clinical chart review. Complete blood count, serum
biochemistries, myeloma stage, performance status,
blood culture results were collected.
Definitions
BSI was defined according to the Centers for Disease
Control and Prevention/National Healthcare Safety Net-
work (CDC/NHSN) guidelines as positive blood culture
related to a febrile episode [10]. In order to explore the
impact of BSIs on early mortality of patients with
multiple myeloma, only blood stream infections within
90 days from the diagnosis of multiple myeloma were
documented. Two bottle cultures were obtained
routinely in each febrile episode. Early mortality was
calculated from date of diagnosis of multiple myeloma
to date of death or date last seen, as appropriate, and
was defined as death within 100 days.
Definite catheter-related blood stream infection (CRI)
was defined as bacteremia or fungemia in a patient with
the central vascular catheter (CVC) with at least one
positive blood culture obtained from a peripheral vein,
clinical manifestations of infection (e.g. fever, chills,
hypotension), and no apparent source of the BSI aside
from the catheter. Nosocomial infection was defined as
infection that becomes evident 48 h or more after ad-
mission. Severe immunoglobulin deficiency was defined
as both of the non-myeloma immunoglobulin levels be-
ing less than one-fourth of the lower normal limit. Cen-
tral vascular access device were grouped into non-
tunneled catheter and tunneled catheter. Non-tunneled
catheter included internal jugular vein central venous
catheter and femoral vein catheter. Tunneled catheter
included implanted port and Perm cath.
Statistical analysis
Patients were separated into BSI (developed within 3
months of diagnosis of myeloma) and non-BSI groups.
Data and survival analyses were compared between two
groups. Early mortality (within 100 days of diagnosis of
multiple myeloma) was the end point. PASW statistics
software (version 18.0, SPSS, Chicago, Illinois) was used
for all statistical analysis. The correlations of variables
between the BSI and non-BSI groups were analyzed by a
Chi-square test. Overall survival (OS) was measured from
the date of diagnosis of multiple myeloma to death of any
cause. Survival was estimated using the Kaplan-Meier
method and the log-rank test was used for comparison of
survival curves. The Cox proportional hazards model was
applied for univariate and multivariate analyses to
determine the prognostic influence of variables on de-
velopment of BSI. Variables with p < 0.05 in univariate ana-
lysis were considered in the multivariate analysis. A P value
< 0.05 in two-tailed tests was considered statistically.
Results
General characteristics
There were 26 BSI patients (11.7%) in this study. Base-
line characteristics of the 26 BSI and 196 non-BSI pa-
tients were listed in Table 1. Between two groups, there
was no statistical difference in gender, age, myeloma
types, status of immunoglobulin deficiency, absolute
lymphocyte count (ALC), and induction chemotherapy.
In the BSI group, patients tended to have a more
advanced stage (ISS stage III, 77% : 48%, p = 0.019), poor
ECOG performance status (>2, 65% : 30%, p < 0.001),
anemia (hemoglobin <10 g/dL, 81% : 55%, p = 0.015),
hypercalcemia (serum calcium > 12.0 mg/dL, 19%: 7%,
p = 0.038), and renal dysfunction (serum creatinine ≥
2.0 mg/dL, 58% : 28%, p = 0.002).
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Outcome analysis
Overall, 24.3% (54/222) of newly diagnosed MM patients
died within 100 days after diagnosis. Thirteen of 26 BSI
patients died within 100 days. Patients who had BSI within
3 months had poorer survival outcomes than those with-
out (mortality rate: 50% vs. 20.9%, p < 0.001) (Fig. 1). Cu-
mulative incidence of BSI is significantly higher in patient
with either more advance stage (p = 0.006) (Fig. 2a) and
poor ECOG performance status (p < 0.001) (Fig. 2b).
Risk factors of BSI
Univariate analysis displayed more advanced stage,
poor performance status, more severe anemia, and
worse renal function as possible risk factors associ-
ated with BSI. However, absolute lymphocyte count
(ALC), < 1000/cumm vs. ≥ 1000/cumm, did not showed
significant difference. Moreover, multivariate analysis
showed only advanced ISS stage (ISS stage III vs. stage I/
II: odds ratio [OR] 2.69, p = 0.049) and poor ECOG
performance status (ECOG PS score > 2 vs. ≤ 2: OR 3.58, p
= 0.005) were the independent risk factors of BSI (Table 2).
Characteristics of BSI patients
There were 26 patients that developed BSI within 3
months of diagnosis, among whom 12 patients (46%) re-
ceived CVC placement during their diagnosis for various
indications such as chemotherapy, fluid resuscitation,
dialysis, and access for transfusion or drug administra-
tion. Two-thirds (8 of 12) of the CVC was non-tunneled.
Definite catheter-related infection (CRI) was docu-
mented in three cases. Patients with CVC placement
had a numerically higher early mortality (8/12, 66.6%)
compared to those without (5/14, 35.7%). Nosocomial
infection accounted for seventy percent (18 of 26) of the
BSI events. Early death occurred in 61% (11 of 18) of
patients with nosocomial BSI and in 25% (2 of 8) of
patients with community-acquired BSI. Sixteen patients
(61.5%) had BSI event after induction chemotherapy.
BSI pathogens and antibiotics susceptibility
Total 27 causative pathogens consisting of 15 (55.6%)
Gram-negative bacilli (GNB), 10 (37.0%) Gram-positive
microorganisms, and 2 (7.4%) fungi were isolated from
26 BSI patients, among which one patient had mixed
Table 1 Baseline characteristics of 222 myeloma patients






Male 141 (72) 17 (65) 0.492
Female 55 (28) 9 (35)
Age≥ 65 y/o 127 (65) 19 (73) 0.402
Myeloma subgroup
IgG 95 (48) 13 (50) 0.741
IgA 63 (32) 9 (35)
Light chain disease 29 (15) 4 (15)
Other typesa 9 (5) 0 (0)
Immunoglobulin status
Severe Ig deficiencyb 177 (90) 23 (88) 0.767
Others 19 (10) 3 (12)
ALC count≥ 1000 (/ul) 138 (70) 17 (65) 0.612
ISS Stage
I 37 (19) 1 (4)
II 64 (33) 5 (19)
III 95 (48) 20 (77) 0.019
ECOG PS >2 59 (30) 17 (65) <.001
Hb < 10 (g/dL) 108 (55) 21 (81) 0.015
Ca > 12.0 (mg/dL) 14 (7) 5 (19) (58) 0.038
Cr≥ 2.0 (mg/dL) 55 (28) 15 0.002
Induction chemotherapy
VAD-based 57 (29) 13 (50)
MP-based 83 (42) 7 (27) 0.064
Othersc 30 (15) 1 (4)
No 26 (13) 5 (19)
Abbreviations: BSI Blood stream infection, IgG Immunoglobulin G, IgA
Immunoglobulin A, Ig Immunoglobulin, ALC Absolute lymphocyte count, ISS
International Staging System, ECOG PS Eastern Cooperative Oncology Group
Performance Status, Hb Hemoglobin, Ca Calcium, Cr Creatinine, VAD Vincristine/
doxorubicin/dexamethasone, MP Melphalan/prednisolone
aOther types include solitary plasmacytomas and plasma cell leukemia
bSevere Ig deficiency is defined as both of the non-myeloma immunoglobulin
levels less than one-fourth of lower normal limit
cIncluding newer regimens such as thalidomide/dexamethasone (TD), bortezomib/
cyclophosphamide/dexamethasone (BCD), bortezomib/dexamethasone (BD),
cyclophosphamide/thalidomide/dexamethasone (CTD), and
bortezomib/cyclophosphamide/dexamethasone (BTD)
*Statistics analysis is used Chi-square or Fisher exact test
Fig. 1 Kaplan-Meier survival curves according to blood stream infection
(BSI) or not. Myeloma patients who had BSI had poorer post-diagnosis
100-day survival outcome than non-BSI patients (100-day mortality rate:
50% vs. 20.9%, p< 0.001). CI Confidence interval
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causative pathogens (Table 3). Coagulase negative
staphylococcus (CNS) (n = 6) was the most common
pathogens followed by Escherichia coli (E. coli) (n = 5).
No significant difference in either early mortality or OS
existed among Gram-positive BSI, Gram-negative BSI or
fungemia (data not shown). For nosocomial BSIs (n = 18,
69%), the frequency of GNB was higher, up to 72.2%
(13/18), and common isolates was E. coli (n = 4) followed
by Klebsiella pneumoniae (K. pneumoniae) (n = 3). For
community-acquired BSIs (n = 8, 31%), Gram-positive mi-
croorganisms (66.7%) were predominant, and CNS (n = 4)
was the most common pathogen. The antibiotic
susceptibility of the causative organisms was shown in
Additional file 1.
Discussion
Despite advances in anti-myeloma therapy and support-
ive care, including the empirical administration of
broad-spectrum antibiotics, effective management of hy-
percalcemia with adequate hydration and intravenous
bisphosphonates, and emergent dialysis for acute renal
failure, pain control, and blood transfusion, up to 24.3%
(54/222) of newly diagnosed MM patients still die within
100 days of their diagnosis in this study. Such deaths are
thought to occur before the maximal beneficial effect of
chemotherapy in reducing tumor load and are compli-
cated with other risk factors, such as comorbidities,
infectious complications, and adverse effects caused by
treatment itself. The early death rate in current study is
considerably higher than previous reported; one import-
ant reason is that a large portion of patients in advanced
stage and high ECOG performance status. Compare with
the largest case study published by Greipp et al. in 2005
[11], we have more patients in ISS stage III (51.8% vs.
39%), and they are older (median age: 72.5 years vs.
60 years). The incidence of patients with age > 80 years
is up to 18%. Furthermore, poor ECOG performance
status > 2 and hemoglobin < 10 account for 34.2 and
58.1% in all patients respectively. Taipei Veterans
General Hospital is a tertiary academic medical center
which accepts final transfer of high risk patients and a
large portion of our patient resources are veterans.
These parameters can explain why early mortality rate is
higher than expected.
BSI is an important cause of morbidity and mortality
in populations with hematological malignancies, and
may contribute to delayed administration of chemother-
apy, increased length of hospitalization, and increased
healthcare expenditure [11, 12]. However, to our know-
ledge, the relationship between BSI and early mortality
in MM was seldom reported in literature. In this study,
26 patients (11.7%) of 222 patients developed BSI within
3 months of newly diagnosed MM and resulted in early
mortality in 13 patients among whom. The mortality
within 100 days after diagnosis of MM patients with and
without bacteremia is 50 and 20.9%. Significantly, the
survival analysis showed a higher rate of early mortality
in patients with BSIs as compared to those without BSIs.
(p < 0.001, Fig. 1). In multivariate analysis, only advanced
ISS stage and poor ECOG performance status were the
independent risk factors of BSI in newly diagnosed
myeloma patients. These two features reflected the
disease severity and poor medical condition, and par-
tially explained the higher susceptibility to BSI.
The absolute lymphocyte count (ALC) has been widely
studied in various malignancies as a marker of host
Fig. 2 Cumulative incidence curves according to myeloma ISS stage
(a) or ECOG performance status (b). The cumulative incidence of BSI
is significantly higher in patients with either more advanced stage
(p = 0.006) (Fig. 2a) or poor ECOG performance status (p < 0.001)
(Fig. 2b). Note early deaths (within 90 days) were the competing
events in the analysis
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immunity. Though its role on EM and BSI in newly
diagnosed MM patients remains undetermined, the
significance on survival and infection risk has been asso-
ciated with multiple myeloma and other hematological
malignancies during different clinical stages of disease
[13–16]. In the UKMRC trials [4], there was a significant
correlation between EM and lymphopenia (< 1000/cumm).
However, ALC did not show any significantly difference in
either the risk of BSI or EM in this study.
Multiple myeloma is characterized with an increased
production of ineffective immunoglobulins with
suppression of non-involved immunoglobulins. More-
over, MM cells can subvert the immune system through
a wealth of potential mechanisms such as immunologic-
ally hostile microenvironment and defective cellular
immunity [17]. We found that neither the type of mono-
clonal gammopathy nor severe non-myelomatous
immunoglobulin deficiency was associated with risk of
BSI. The complexity of immune dysfunction in MM may
partially explain this insignificance.
Wang et al. reported that GNB accounted for 78.2%
of bacteremia in 266 patients with hematologic malig-
nancies, followed by Gram-positive cocci (GPC),
20.8%, in our hospital from 1999 to 2002 [18]. The
spectrum of causative organisms and related antibiotic
susceptibility were similar in both studies. This infor-
mation is very helpful in choosing adequate empirical
antimicrobial agents for BSI, especially in patients
with high risk of mortality.
Despite beyond the scope of current study, several
studies have indicated that novel anti-myeloma agents
may reduce early mortality. Tan et al. demonstrated that
the frontline use of bortezomib compared to its sequen-
tial may avert early mortality (death within 2 years of
diagnosis), especially among patients with high-risk MM
[19]. Kumar et al. found that early mortality (death
within 1 year of diagnosis) was significantly lower among
the patients who had received one of the newer drugs as
part of their initial therapy (8% vs. 19%; p < 0.001) [20].
They also identified age > 70, serum albumin < 3.5 gm/dL,
and serum beta2 microglobulin > 6.5 mg/dL as factors in-
dependently predicting early mortality [20]. These three
parameters are similar to advanced ISS stage and poor
ECOG performance status proposed in our study.
There are several limitations of our study, first is the
retrospective design of the study which may have patient
and treatment selection biases. Secondly, the study
period is between November 2002 and December 2008.
The fact that very few patients receiving newer induction
agents (such as proteasome inhibitors and/or immuno-
modulating drugs limits our general application to mye-
loma patients who are now receiving these newer agents
as induction therapy. Due to the individualized decisions
on the induction regimens, it is difficult for us to analyze
the impact of newer agents on bloodstream infections.
Moreover, in countries with limited health resources, the
traditional therapies remain the backbone of combin-
ation therapy for multiple myeloma, and novel agents
Table 2 Univariate and multivariate analysis for blood stream infection
Univariate Multivariate
Odds ratio 95% CI P value* Odds ratio 95% CI P value*
Gender (female vs. male) 1.36 0.571–3.266 0.49 - - -
Age (≥ 65 vs. < 65) 1.48 0.591–3.681 0.40 - - -
Myeloma subgroup
IgG vs. Non-IgG 1.06 0.469–2.410 0.88 - - -
IgA vs. Non-IgA 1.12 0.472–2.646 0.80
Immunoglobulin status 1.18 0.324–4.303 0.80 - - -
Severe Ig deficiencya vs. Others
ISS stage
III vs. I/II 3.54 1.365–9.203 <0.01* 2.69 1.003–7.190 0.049
ECOG PS
Score > 2 vs. 0–2 4.39 1.849–10.403 <0.01* 3.58 1.478–8.690 0.005
Hb (< 10 g/dL vs. ≥ 10 g/dL) 3.422 1.240–9.444 0.02* - - -
Ca (> 12 mg/dL vs. < 12 mg/dL) 3.095 1.013–9.454 0.04* - - -
Cr (≥ 2.0 mg/dL vs. < 2.0 mg/dL) 3.091 1.341–7.126 0.01* - - -
ALC (< 1000/cumm vs. ≥ 1000/cumm) 1.251 0.527–2.968 0.61
Abbreviations: IgG Immunoglobulin G, IgA Immunoglobulin A, Ig Immunoglobulin, ISS International Staging System, ECOG PS Eastern Cooperative Oncology Group
Performance Status, Hb Hemoglobin, Ca Calcium; Cr Creatinine, ALC Absolute lymphocyte count
aSevere Ig deficiency: both of the non-myeloma immunoglobulin levels less than one-fourth of lower normal limit
*Significant p < 0.05 in univariate models were entered in the Cox regression multivariate model using conditional backward analysis
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ICT regimen Catheter type Definite
CRIb
Pathogen Empirical antibiotics Early death
(< 100day)
Nosocomial BSIa
1 (90) - - - - Coagulase-negative
Staphylococcus species
Ceftazidime/isepamicin Y









4 (27) - MP - - Klebsiella pneumoniae Cefepime -
5 (62) Y MPT Non-tunneled CVC Y Klebsiella pneumoniae Ciprofloxacin
- > Imipenem/teicoplanin
Y
6 (78) - - - - Escherichia coli Y
7 (198) Y VAD Non-tunneled CVC - Escherichia coli Cefuroxime/clindamycin Y
8 (168) Y VAD/thalidomide Non-tunneled
PICC
- Escherichia coli Imipenem/vancomycin/
amikin
Y





Y VAD - - Enterobacter gergoviae Oxacillin -
11 (14) Y VAD Implanted port - Enterobacter cloacae -
12 (94) - VAD Non-tunneled CVC - Pseudomonas Aeruginosa Cefepime Y
13
(115)
Y VAD Implanted port - Proteus mirabilis Levofloxacin -





Y VAD Non-tunneled CVC - Staphylococcus aureus -
16 (71) - - Non-tunneled CVC Y Serratia marcescens Y
17 (61) Y MP Non-tunneled CVC - Yeast like-Trichosporon
asahii
Cefepime/azithromycin Y




1 (221) - - - - Coagulase-negative
Staphylococcus species
Flomoxef -
2 (41) Y VAD - - Coagulase-negative
Staphylococcus species
Piperacillin/tazobactam -
3 (211) Y MP - - Coagulase-negative
Staphylococcus species
-
4 (205) - - - - Streptococcus Meropenem/vancomycin/
metronidazole
Y
5 (137) - - - - Streptococcus pneumoniae -
6 (6) - MP - - Escherichia coli Cephalexin/isepamicin -
7 (106) - VAD Non-tunneled
CVC
- Pseudomonas aeruginosa Cefoperazone -
8 (46) Y MP Tunneled CVC
(Permcath)
- Lactobacillus species Moxifloxacin Y
Abbreviations: BSI Blood stream infection, ICT Induction chemotherapy, CRI Catheter related infection, VAD Vincristine/doxorubicin/dexamethasone, MP Melphalan/
prednisolone, MPT Melphalan/prednisolone/thalidomide, CVC Central venous catheter, PICC Peripherally inserted central catheter
aNosocomial infection is defined as infection become evident 48 h or more after admission
bDefinite CRI (catheter related infection) is defined as bacteremia/fungemia in a patient with an intravascular catheter with at least one positive blood culture obtained from
a peripheral vein, clinical manifestations of infection (i.e., fever, chills, and/or hypotension), and no apparent source for the bloodstream infection except the catheter
Huang et al. BMC Infectious Diseases  (2017) 17:33 Page 6 of 8
may not be permitted as first-line therapy. Our results
need further validation in the era of novel agents. In our
study, early mortality was defined arbitrarily as death
within 100 days to approximately estimate the impact of
bloodstream infections on outcome. Therefore, individ-
ual specific cause of deaths, as well as competing death
events could not be assessed in the survival analysis. In
addition, the impact of BSI on outcome could not be
assessed on patients developing BSI within 90 days but
dying after 100 days, although these patients were also
likely died of infections.
Conclusions
In conclusion, we stress that BSI in newly diagnosed
MM patients is a frequently observed clinical condition
that requires prompt recognition and adequate anti-
microbial treatment, outside of anti-myeloma therapies,
to reduce the risk of early mortality. Patients with more
advanced ISS stage and poor ECOG performance status
should be classified as a high risk group. Epidemiological
data of common pathogens with antibiotic susceptibility
is useful in improving clinical decision-making. More
prospective studies are required to confirm the impact
of the frontline use of novel agents in early mortality of
MM and the accuracy of the developed scoring system
to predict the risk of BSI as well as the role of antimicro-
bial prophylaxis in newly diagnosed patients.
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